https://www.oncnursingnews.com/view/15-months-of-bevacizumab-remains-ideal-length-for-patients-with-ovarian-cancer
0
0
11/18/22 at 3:04pm
Organization
Oncnursingnews.com
Author
Lindsay Fischer
Increasing the duration of bevacizumab treatment did not improve progression-free survival for patients with ovarian cancer.
Create an account
or login to join the discussion